These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

118 related articles for article (PubMed ID: 2129649)

  • 1. The effect of colestipol dose on postprandial serum bile acid concentration: assessment by an enzymic bioluminescence procedure.
    Fleishaker JC; Rossi SS; Smith RB; Welshman IR; Daei F; Angellotti MA; Hofmann AF
    Aliment Pharmacol Ther; 1990 Dec; 4(6):623-33. PubMed ID: 2129649
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of the bile-acid sequestrant colestipol on postprandial serum bile-acid concentration: evaluation by bioluminescent enzymic analysis.
    Rossi SS; Wayne ML; Smith RB; Wright CE; Andreadis NA; Hofmann AF
    Aliment Pharmacol Ther; 1989 Feb; 3(1):41-6. PubMed ID: 2491457
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The effects of colestipol tablets compared with colestipol granules on plasma cholesterol and other lipids in moderately hypercholesterolemic patients.
    Insull W; Davidson MH; Demke DM; Dujovne CA; Eckert SM; Ginsberg D; Goldberg AC; Hodis HN; Hughes TA; Kane JP
    Atherosclerosis; 1995 Jan; 112(2):223-35. PubMed ID: 7772081
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effectiveness of low-dose colestipol therapy in patients with moderate hypercholesterolemia.
    Superko HR; Greenland P; Manchester RA; Andreadis NA; Schectman G; West NH; Hunninghake D; Haskell WL; Probstfield JL
    Am J Cardiol; 1992 Jul; 70(2):135-40. PubMed ID: 1626496
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Long-term effects of colestipol (U-26,597 A) on plasma lipids in familial type II hyperbetalipoproteinaemia.
    Fellin R; Briani G; Balestrieri P; Baggio G; Baiocchi MR; Crepaldi G
    Atherosclerosis; 1975; 22(3):431-45. PubMed ID: 1201145
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison of hypocholesterolemic activities of the bile acid sequestrants cholestyramine and colestipol hydrochloride in cholesterol fed SEA quail.
    Day CE
    Artery; 1990; 17(5):281-8. PubMed ID: 2396902
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Colestipol at varying dosage intervals in the treatment of moderate hypercholesterolaemia.
    Lyons D; Webster J; Fowler G; Petrie JC
    Br J Clin Pharmacol; 1994 Jan; 37(1):59-62. PubMed ID: 8148218
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of colestipol hydrochloride on cholesterol and bile acids absorption in the rat intestinal tract.
    Fujihashi T; Munekiyo K; Meshi T
    J Pharmacobiodyn; 1981 Aug; 4(8):552-8. PubMed ID: 7299619
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Long term treatment of familial hypercholesterolemia with Colestipol, a new anionic exchange resin (author's transl)].
    Briani G; Fellin R; Balestrieri P; Baggio G; Baiocchi MR; Crepaldi G
    G Ital Cardiol; 1975; 5(3):390-404. PubMed ID: 1149965
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Hypocholesterolemic activity of colestipol hydrochloride in SEA quail.
    Day CE
    Artery; 1989; 17(1):49-59. PubMed ID: 2589993
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of colestipol hydrochloride and neomycin sulfate on cholesterol turnover in the rat.
    Phillips WA; Elfring GL
    Lipids; 1977 Jan; 12(1):10-5. PubMed ID: 834115
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Low-dose colestipol plus probucol for hypercholesterolemia.
    Dujovne CA; Chernoff SB; Krehbiel P; Jackson B; DeCoursey S; Taylor H
    Am J Cardiol; 1984 Jun; 53(11):1514-8. PubMed ID: 6375337
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of colestipol hydrochloride on drug absorption in the rat II.
    Phillips WA; Ratchford JM; Schultz JR
    J Pharm Sci; 1976 Sep; 65(9):1285-91. PubMed ID: 966139
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The effects of colestipol when combined with clofibrate in the treatment of severe hyperlipidemia. Short-term and long-term studies.
    Lithell H; Vessby B; Boberg J; Hellsing K
    Atherosclerosis; 1980 Oct; 37(2):175-86. PubMed ID: 7000089
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Combination therapy with colestipol and psyllium mucilloid in patients with hyperlipidemia.
    Spence JD; Huff MW; Heidenheim P; Viswanatha A; Munoz C; Lindsay R; Wolfe B; Mills D
    Ann Intern Med; 1995 Oct; 123(7):493-9. PubMed ID: 7661492
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Colestipol: a review of its pharmacological properties and therapeutic efficacy in patients with hypercholesterolaemia.
    Heel RC; Brogden RN; Pakes GE; Speight TM; Avery GS
    Drugs; 1980 Mar; 19(3):161-80. PubMed ID: 6988203
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Safety and efficacy of long-term diet and diet plus bile acid-binding resin cholesterol-lowering therapy in 73 children heterozygous for familial hypercholesterolemia.
    Glueck CJ; Mellies MJ; Dine M; Perry T; Laskarzewski P
    Pediatrics; 1986 Aug; 78(2):338-48. PubMed ID: 3526270
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The effects of colestipol resin and of colestipol plus clofibrate on the turnover of plasma cholesterol in man.
    Goodman DS; Noble RP; Dell RB
    J Clin Invest; 1973 Oct; 52(10):2646-55. PubMed ID: 4729058
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Complementarity of colestipol, niacin, and lovastatin in treatment of severe familial hypercholesterolemia.
    Malloy MJ; Kane JP; Kunitake ST; Tun P
    Ann Intern Med; 1987 Nov; 107(5):616-23. PubMed ID: 3662275
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Regression of coronary artery disease as a result of intensive lipid-lowering therapy in men with high levels of apolipoprotein B.
    Brown G; Albers JJ; Fisher LD; Schaefer SM; Lin JT; Kaplan C; Zhao XQ; Bisson BD; Fitzpatrick VF; Dodge HT
    N Engl J Med; 1990 Nov; 323(19):1289-98. PubMed ID: 2215615
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.